Key Publications

A systematic review of progranulin concentrations in biofluids in over 7,000 people-assessing the pathogenicity of GRN mutations and other influencing factors.

Swift IJ, Rademakers R, Finch N, Baker M, Ghidoni R et al. Alzheimers Res Ther. 2024.

Differential patterns of lysosomal dysfunction are seen in the clinicopathological forms of primary progressive aphasia.

Swift IJ, Sjödin S, Gobom J, Brinkmalm A, Blennow K et al. J Neurol. 2024.

Fluid biomarkers in frontotemporal dementia: past, present and future.

Swift IJ, Sogorb-Esteve A, Heller C, Synofzik M, Otto M, et al. J Neurol Neurosurg Psychiatry. 2021.

Variable clinical phenotype in TBK1 mutations: case report of a novel mutation causing primary progressive aphasia and review of the literature.

Swift IJ, Bocchetta M, Benotmane H, Woollacott IO, Shafei R, Rohrer JD. Neurobiol Aging. 2021.

Differential impairment of cerebrospinal fluid synaptic biomarkers in the genetic forms of frontotemporal dementia.

Sogorb-Esteve A, Nilsson J, Swift IJ, Heller C, Bocchetta M, et al. Alzheimers Res Ther. 2022.

Neurofilament light oligomers in neurodegenerative diseases: quantification by homogeneous immunoassay in cerebrospinal fluid. 

Meda FJ, Knowles K, Swift IJ, Sogorb-Esteve A, Rohrer JD, et al., BMJ Neurol Open. 2023.

Elevated CSF and plasma complement proteins in genetic frontotemporal dementia: results from the GENFI study.

van der Ende EL, Heller C, Sogorb-Esteve A, Swift IJ, McFall D, et al. J Neuroinflammation. 2022.

Development of a sensitive trial-ready poly(GP) CSF biomarker assay for C9orf72-associated frontotemporal
dementia and amyotrophic lateral sclerosis.

Wilson KM, Katona E, Glaria I, Carcolé M, Swift IJ, et al. J Neurol Neurosurg Psychiatry. 2022.

CSF glial markers are elevated in a subset of patients with genetic frontotemporal dementia. 

Woollacott IOC, Swift IJ, Sogorb-Esteve A, Heller C, Knowles K, et al. Ann Clin Transl Neurol. 2022.